ArticleJournal of nanobiotechnology2023
Programmable DNA hydrogel provides suitable microenvironment for enhancing autophagy-based therapies in intervertebral disc degeneration treatment.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- HDAC1 maintains metabolic homeostasis in nucleus pulposus cells via post-translational modification interactions with YBX1.Experimental & molecular medicine · 2026Article
- A Challenge-Oriented Review of Delivery Systems for Cell and Gene Therapies in Intervertebral Disc Degeneration.Bioengineering (Basel, Switzerland) · 2026Review
- Biomaterial-assisted gene therapy for bone repair.Materials today. Bio · 2026Review
- Functional nucleic acid Hydrogels: Paving the way for Next-generation bone and cartilage regeneration.Materials today. Bio · 2026Review
- Antioxidant biomaterials in intervertebral disc regeneration: current status and future clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- From pathogenesis to treatment: the role of autophagic cell death in GONFH and its potential mitigation by naringenin.Theranostics · 2026Article
- From molecular regulation to tissue repair: hydrogels in the fight against intervertebral disc degeneration.Annals of medicine · 2025Review
- Understanding the Microenvironment of Intervertebral Disc Degeneration: A Comprehensive Review of Pathophysiological Insights and Therapeutic Implications.International journal of molecular sciences · 2025Review
- Exosome Therapy: A Promising Avenue for Treating Intervertebral Disc Degeneration.Tissue engineering and regenerative medicine · 2025Review
- Biomaterial-Based Nucleic Acid Delivery Systems for In Situ Tissue Engineering and Regenerative Medicine.International journal of molecular sciences · 2025Review
- Gubi Decoction Ameliorates Porous Cartilage Endplate in an Intervertebral Disc Degeneration Model Mouse Through Inhibition of NF-κB Activity and Pyroptosis.Journal of inflammation research · 2025Article
- MicroRNAs regulating apoptosis and delivery strategies for treating intervertebral disc degeneration.Frontiers in cell and developmental biology · 2025Review
- Tissue engineering strategies for treating intervertebral disc degeneration.Frontiers in bioengineering and biotechnology · 2025Review
- Innovative strategies in combating intervertebral disc degeneration: pathological mechanisms and biomaterial advancements.Frontiers in bioengineering and biotechnology · 2025Review
- Nano-Drug Delivery System Targeting the Oxidative Stress Microenvironment: A Prospective Strategy for Intervertebral Disc Degeneration Treatment.International journal of nanomedicine · 2025Review
- Progress in the Application of Hydrogels in Intervertebral Disc Repair: A Comprehensive Review.Current pain and headache reports · 2024Review
- Application trends and strategies of hydrogel delivery systems in intervertebral disc degeneration: A bibliometric review.Materials today. Bio · 2024Review
- DNA-based nanostructures for RNA delivery.Medical review (2021) · 2024Review
- Hydrogel-Based Strategies for Intervertebral Disc Regeneration: Advances, Challenges and Clinical Prospects.Gels (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
The pathogenesis of intervertebral disc degeneration (IVDD) is attributed to metabolic dysregulation within the extracellular matrix and heightened apoptosis of nucleus pulposus cells (NPC). Therefore, a potential therapeutic strategy for managing IVDD involves the reestablishment of metabolic equilibrium within the extracellular matrix and the suppression of excessive myeloid cell apoptosis. The microRNA, miR-5590, displays marked differential expression in degenerative nucleus pulposus (NP) tissues and exerts a direct influence on the regulation of DDX5 expression. This, in turn, modulates mammalian target of rapamycin (mTOR) phosphorylation, thereby impacting autophagy and apoptosis. However, ensuring the smooth delivery of miRNA to a specific injury site poses a significant challenge. To address this issue, a multifunctional DNA hydrogel was developed and subsequently loaded with miR-5590 via spherical nucleic acids (SNAs) for the treatment of IVDD. The hydrogel, which exhibits versatility, has the potential to be administered through injection at the site of injury, resulting in a consistent and prolonged release of miR-5590. This leads to the creation of a genetic microenvironment within the NP, which triggers the onset of autophagy in NPCs and subsequently suppresses apoptosis. As a result, this process regulates the metabolic equilibrium within the extracellular matrix, thereby impeding the in vitro and in vivo progression of IVDD. The amalgamation of miRNAs and biomaterials offers a promising therapeutic strategy for the management of IVDD in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.